- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Kodak acquires CAD technology
As part of an increasingly aggressive strategy to focus on digital imaging, Eastman Kodak has acquired software firm MiraMedica and its computer-aided detection technology. The price paid for the privately held Los Gatos, CA, company was not disclosed.
As part of an increasingly aggressive strategy to focus on digital imaging, Eastman Kodak has acquired software firm MiraMedica and its computer-aided detection technology. The price paid for the privately held Los Gatos, CA, company was not disclosed. Kodak is picking up several key employees as part of the deal. MiraMedica's chief technology officer, Wido Menhardt, will become general manager of CAD operations. Company president and CEO Caren Mason will serve as a business consultant during the transition of CAD operations to Kodak. The CAD software, which was the target of the acquisition, automatically highlights suspicious areas on images either acquired digitally or digitized from film. It will be sold as a stand-alone product and as a component of Kodak digital capture and image and information management systems. The CAD technology is built on a platform licensed exclusively from Lockheed Martin Space Systems and the University of South Florida.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
